Inhaled anti-asthma therapies following hormone therapy in women: a nationwide cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Inhaled anti-asthma therapies following hormone therapy in women : a nationwide cohort study. / Hansen, Erik Soeren Halvard; Aasbjerg, Kristian; Moeller, Amalie Lykkemark; Meaidi, Amani; Gade, Elisabeth Juul; Torp-Pedersen, Christian; Backer, Vibeke.
I: ERJ Open Research, Bind 8, Nr. 1, 00611-2021, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inhaled anti-asthma therapies following hormone therapy in women
T2 - a nationwide cohort study
AU - Hansen, Erik Soeren Halvard
AU - Aasbjerg, Kristian
AU - Moeller, Amalie Lykkemark
AU - Meaidi, Amani
AU - Gade, Elisabeth Juul
AU - Torp-Pedersen, Christian
AU - Backer, Vibeke
N1 - Publisher Copyright: © The authors 2022.
PY - 2022
Y1 - 2022
N2 - Research question Does menopausal hormone therapy (HT) with exogenous oestrogens and progestogens change the use of inhaled anti-asthma medications in women with asthma? Methods In a population-based matched cohort study using the Danish registries, we included women with asthma aged 45–65 years from 1 June 1995 to 30 June 2018. We investigated whether HT with oestrogen and/or progestogens was associated with changes in use of inhaled anti-asthma therapies in the 12 months following initiation. We used exposure density matching to match exposed subjects with unexposed subjects on age, household income and level of education. An exposed subject was defined as receiving HT. We calculated mean dose of medications and odds ratios of increases in the 12 months following HT initiation. Results We included 139 483 women with asthma, of whom 116 014 (83.2%) were unexposed subjects and 23 469 (16.8%) exposed subjects. Mean±SD age was 53.0±5.2 years. Initiation of HT was not consistently associated with increased mean doses of inhaled corticosteroids (ICS), or long-and short-acting β2-agonists. Women receiving systemic oestrogens had increased odds ratios of large increases (>100 µg) in ICS at 6 months (OR 1.09; 95% CI 1.04–1.13; p<0.001) and 9 months (OR 1.07; 95% CI 1.03–1.12; p<0.001). Progestogens were protective against increases in ICS at 6 and 9 months (OR 0.87; 95% CI 0.82–0.93; p<0.001; and OR 0.86; 95% CI 0.81–0.91; p<0.001). Conclusion Initiation of HT did not change the use of inhaled medications in asthma. However, detrimental effects of oestrogen, as well as beneficial effects of progestogens, cannot be excluded.
AB - Research question Does menopausal hormone therapy (HT) with exogenous oestrogens and progestogens change the use of inhaled anti-asthma medications in women with asthma? Methods In a population-based matched cohort study using the Danish registries, we included women with asthma aged 45–65 years from 1 June 1995 to 30 June 2018. We investigated whether HT with oestrogen and/or progestogens was associated with changes in use of inhaled anti-asthma therapies in the 12 months following initiation. We used exposure density matching to match exposed subjects with unexposed subjects on age, household income and level of education. An exposed subject was defined as receiving HT. We calculated mean dose of medications and odds ratios of increases in the 12 months following HT initiation. Results We included 139 483 women with asthma, of whom 116 014 (83.2%) were unexposed subjects and 23 469 (16.8%) exposed subjects. Mean±SD age was 53.0±5.2 years. Initiation of HT was not consistently associated with increased mean doses of inhaled corticosteroids (ICS), or long-and short-acting β2-agonists. Women receiving systemic oestrogens had increased odds ratios of large increases (>100 µg) in ICS at 6 months (OR 1.09; 95% CI 1.04–1.13; p<0.001) and 9 months (OR 1.07; 95% CI 1.03–1.12; p<0.001). Progestogens were protective against increases in ICS at 6 and 9 months (OR 0.87; 95% CI 0.82–0.93; p<0.001; and OR 0.86; 95% CI 0.81–0.91; p<0.001). Conclusion Initiation of HT did not change the use of inhaled medications in asthma. However, detrimental effects of oestrogen, as well as beneficial effects of progestogens, cannot be excluded.
U2 - 10.1183/23120541.00611-2021
DO - 10.1183/23120541.00611-2021
M3 - Journal article
C2 - 35350280
AN - SCOPUS:85127650264
VL - 8
JO - ERJ Open Research
JF - ERJ Open Research
SN - 2312-0541
IS - 1
M1 - 00611-2021
ER -
ID: 313774387